Essential Healthcare News
SEE OTHER BRANDS

Global take on healthcare and wellness news

Essential Healthcare News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.

Press releases published on May 6, 2025

BetterLife Announces Debt Settlements

BetterLife Announces Debt Settlements

VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic …

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development

Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR …

WW International, Inc. Schedules Investor Conference Call

WW International, Inc. Schedules Investor Conference Call

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, announced that it will host an investor conference call today May 6, 2025, at 6:00 p. …

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop …

Information regarding the total number of voting rights and   total number of shares of the Company as of April 30, 2025

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 …

Information relative au nombre total des droits de vote et  d’actions composant le capital social au 30 avril 2025

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025

Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 avril 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 …

Cellectis to Report First Quarter Financial Results on May 12, 2025

Cellectis to Report First Quarter Financial Results on May 12, 2025

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced …

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place …

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25 New strategic collaboration with Lilly ExploR…

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of …

MacroGenics Announces Date of First Quarter 2025 Financial Results

MacroGenics Announces Date of First Quarter 2025 Financial Results

ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today …

Sienna Reports First Quarter 2025 Financial Results and Continues Platform Expansion

Sienna Reports First Quarter 2025 Financial Results and Continues Platform Expansion

MARKHAM, Ontario, May 06, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three months ended March 31, 2025. Q1 2025 Highlights Average Same Property Occupancy in …

Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance

Jin Medical International Ltd. – Nasdaq Minimum Bid Price Non-Compliance

Changzhou City, China, May 06, 2025 (GLOBE NEWSWIRE) -- Jin Medical International Ltd. (NASDAQ: ZJYL) (the “Company”) today announced that on May 2, 2025, it received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department (the …

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   “The …

SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025

SANTA CLARA, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming 2025 BofA Securities Healthcare …

Supernus Announces First Quarter 2025 Financial Results

Supernus Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024. First quarter 2025 total revenues …

Pennant Reports First Quarter 2025 Results

Pennant Reports First Quarter 2025 Results

EAGLE, Idaho, May 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results, reporting GAAP diluted …

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance

Total revenues increased 49% year-over-year to $65.7 million with telehealth revenue up 70% Adjusted EBITDA increased to $8.7 million from $0.1 million in the year-ago period Telehealth adjusted EBITDA increased to $5.3 million from a loss of $1.3 million …

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude’s once daily, oral SMARCA2 degrader, PRT7732 is …

89bio to Participate in Upcoming Investor Conferences

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service